Monthly prophylactic garadacimab significantly reduces hereditary angioedema attacks
1. Compared to placebo, monthly garadacimab significantly reduced the number of hereditary angioedema attacks per month. 2. Overall, garadacimab was well-tolerated, with the most common adverse events being upper respiratory tract infections, nasopharyngitis, and headaches. Evidence Rating Level: 1 (Excellent) Study Rundown: Hereditary angioedema (HAE) is a rare genetic disorder that is characterized by recurring
Rating Level Lanadelumab Compared With Placebo Hereditary Angioedema C1 Esterase Inhibitor C1 Inhibitor Deficiency Factor Xiia
Source: 2minutemedicine.com